Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet

Antiviral Therapy

Volumn 12, Issue 6, 2007, Pages 877-888

  Bonnafous, Pascale ^a   Naesens, Lieve ^b   Petrella, Stéphanie ^c   Gautheret Dejean, Agnès ^a,d   Boutolleau, David ^a   Sougakoff, Wladimir ^c   Agut, Henri ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c INSERM   (France)

^d FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADEFOVIR; CIDOFOVIR; DNA POLYMERASE; FOSCARNET; FOSCARNET SODIUM; GANCICLOVIR; RECOMBINANT ENZYME; TENOFOVIR;

AMINO ACID SUBSTITUTION; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DNA DETERMINATION; DRUG EFFECT; DRUG MECHANISM; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HERPES VIRUS INFECTION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 6; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN STRUCTURE; VIRUS GENE; VIRUS ISOLATION;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; CATALYTIC DOMAIN; CELL LINE; CYTOMEGALOVIRUS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FOSCARNET; GENES, VIRAL; HERPESVIRUS 6, HUMAN; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT;

EID: 34848865739     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Yamanishi K, Okuno T, Shiraki K, et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1988; 1:1065-1067.
2. Astriti M, Zeller V, Boutolleau D, et al. Fatal HHV-6 associated encephalitis in an HIV-1 infected patient treated with cidofovir. J Infect 2006; 52:237-242.
3. Ljungman P, Singh N. Human herpesvirus-6 infection in solid organ and stem cell transplant recipients. J Clin Virol 2006; 37 Suppl 1:S87-S91.
4. Lehto JT, Halme M, Tukiainen P, Harjula A, Sipponen J, Lautenschlager I. Human herpesvirus-6 and -7 after lung and heart-lung transplantation. J Heart Lung Transplant 2007; 26:41-47.
5. Harma M, Hockerstedt K, Lyytikainen O, Lautenschlager I. HHV-6 and HHV-7 antigenemia related to CMV infection after liver transplantation. J Med Virol 2006; 78:800-805.
6. Ablashi DV, Eastman HB, Owen CB, et al. Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients. J Clin Virol 2000; 16:179-191.
7. Alvarez-Lafuente R, De Las Heras V, Bartolome M, Garcia-Montojo M, Arroyo R. Human herpesvirus 6 and multiple sclerosis: a one-year follow-up study. Brain Pathol 2006; 16:20-27.
8. Jacobson S. The emerging role of HHV-6 in neurologic disease: lesson from multiple sclerosis and epilepsy. Retrovirology 2006; 3 Suppl 1:S64.
9. Razonable RR, Rivero A, Brown RA, et al. Detection of simultaneous beta-herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. Clin Transplant 2003; 17:114-120.
10. Naesens L, De Clercq E. Recent developments in herpesvirus therapy. Herpes 2001; 8:12-16.
11. De Clercq E, Naesens L, De Bolle L, Schols D, Zhang Y, Neyts J. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Med Virol 2001; 11:381-395.
12. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006; 71:154-163.
13. Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005; 49:873-883.
14. Manichanh C, Olivier-Aubron C, Lagarde JP, et al. Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo. J Gen Virol 2001; 82:2767-2776.
15. Safronetz D, Petric M, Tellier R, Parvez B, Tipples GA. Mapping ganciclovir resistance in the human herpesvirus-6 U69 protein kinase. J Med Virol 2003; 71:434-439.
16. Xiong X, Smith JL, Chen MS. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob Agents Chemother 1997; 41:594-599.
17. Xiong X, Smith JL, Kim C, Huang ES, Chen MS. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochem Pharmacol 1996; 51:1563-1567.
18. Cihlar T, Fuller MD, Cherrington JM. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J Virol 1998; 72:5927-5936.
19. Huang L, Ishii KK, Zuccola H, et al. The enzymological basis for resistance of herpesvirus DNA polymerase mutants to acyclovir: relationship to the structure of alpha-like DNA polymerases. Proc Natl Acad Sci U S A 1999; 96:447-452.
20. Crumpacker CS. Mechanism of action of foscarnet against viral polymerases. Am J Med 1992; 92:3S-7S.
21. Eriksson B, Oberg B, Wahren B. Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin. Biochim Biophys Acta 1982; 696:115-123.
22. Tchesnokov EP, Gilbert C, Boivin G, Gotte M. Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet. J Virol 2006; 80:1440-1450.
23. Derse D, Bastow KF, Cheng Y. Characterization of the DNA polymerases induced by a group of herpes simplex virus type I variants selected for growth in the presence of phosphonoformic acid. J Biol Chem 1982; 257:10251-10260.
24. Marchand B, Tchesnokov EP, Gotte M. The pyrophosphate analogue foscarnet traps the pre-translocational state of HIV-1 reverse transcriptase in a Brownian ratchet model of polymerase translocation. J Biol Chem 2007; 282:3337-3346.
25. Morfin F, Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003; 26:29-37.
26. Manichanh C, Grenot P, Gautheret-Dejean A, Debre P, Huraux JM, Agut H. Susceptibility of human herpesvirus 6 to antiviral compounds by flow cytometry analysis. Cytometry 2000; 40:135-140.
27. Mace M, Manichanh C, Bonnafous P, et al. Real-time PCR as a versatile tool for investigating the susceptibility of human herpesvirus 6 to antiviral agents. Antimicrob Agents Chemother 2003; 47:3021-3024.
28. Bonnafous P, Gautheret-Dejean A, Boutolleau D, Caiola D, Agut H. Persistence of DNA in cell cultures may jeopardize the analysis of human herpesvirus 6 dynamics by means of real-time PCR. J Virol Methods 2005; 125:95-98.
29. Gautheret-Dejean A, Manichanh C, Thien-Ah-Koon F, et al. Development of a real-time polymerase chain reaction assay for the diagnosis of human herpesvirus-6 infection and application to bone marrow transplant patients. J Virol Methods 2002; 100:27-35.
30. De Bolle L, Manichanh C, Agut H, De Clercq E, Naesens L. Human herpesvirus 6 DNA polymerase: enzymatic parameters, sensitivity to ganciclovir and determination of the role of the A961V mutation in HHV-6 ganciclovir resistance. Antiviral Res 2004; 64:17-25.
31. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res 2003; 31:3381-3385.
32. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997; 18:2714-2723.
33. Peitsch M. Protein modeling by E-mail. Bio/Technology 1995; 13:658-660.
34. Liu S, Knafels JD, Chang JS, et al. Crystal structure of the herpes simplex virus 1 DNA polymerase. J Biol Chem 2006; 281:18193-18200.
35. Ginalski K, Elofsson A, Fischer D, Rychlewski L. 3D-Jury: a simple approach to improve protein structure predictions. Bioinformatics 2003; 19:1015-1018.
36. Brünger AT, Adams PD, Clore GM, et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998; 54:905-921.
37. Franklin MC, Wang J, Steitz TA. Structure of the replicating complex of a pol alpha family DNA polymerase. Cell 2001; 105:657-667.
38. DeLano WL. The PyMOL Molecular Graphics System. 2002. Palo Alto, CA: DeLano Scientific. Available from http://www.pymol.org
39. Boutolleau D, André-Garnier E, Bonnafous P, Agut H, Gautheret-Dejean A. Activation of human herpesvirus 6 (HHV-6) replication by human cytomegalovirus (HCMV) in human fibroblast culture J Clin Virol 2006; 37 Suppl 1:S97.
40. Ducancelle A, Gravisse J, Alain S, et al. Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet. J Virol Methods 2005; 125:145-151.
41. Gilbert C, Boivin G. New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure. Antimicrob Agents Chemother 2005; 49:4860-4866.
42. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003; 16:569-596.
43. Scott GM, Weinberg A, Rawlinson WD, Chou S. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother 2007; 51:89-94.
44. Ducancelle A, Champier G, Alain S, Petit F, Le Pors MJ, Mazeron MC. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. Antivir Ther 2006; 11:537-540.
45. Eckle T, Prix L, Jahn G, et al. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 2000; 96:3286-3289.
46. Mousavi-Jazi M, Schloss L, Drew WL, et al. Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity. J Clin Virol 2001; 23:1-15.
47. Springer KL, Chou S, Li S, et al. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol 2005; 43:208-213.
48. Ducancelle A, Belloc S, Alain S, et al. Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy. J Clin Virol 2004; 29:241-247.
49. Shi R, Azzi A, Gilbert C, Boivin G, Lin SX. Three-dimensional modeling of cytomegalovirus DNA polymerase and preliminary analysis of drug resistance. Proteins 2006; 64:301-307.
50. Isegawa Y, Mukai T, Nakano K, et al. Comparison of the complete DNA sequences of human herpesvirus 6 variants A and B. J Virol 1999; 73:8053-8063.